Walleye Capital LLC bought a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX – Free Report) in the first quarter, Holdings Channel.com reports. The firm bought 108,008 shares of the company’s stock, valued at approximately $2,148,000.
A number of other institutional investors and hedge funds have also recently bought and sold shares of BCAX. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Bicara Therapeutics during the 4th quarter valued at about $45,000. Legal & General Group Plc lifted its stake in Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after purchasing an additional 1,233 shares in the last quarter. Larson Financial Group LLC boosted its holdings in shares of Bicara Therapeutics by 1,015.5% during the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after purchasing an additional 3,595 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after purchasing an additional 3,866 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its position in shares of Bicara Therapeutics by 385.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock valued at $97,000 after purchasing an additional 4,585 shares in the last quarter.
Insiders Place Their Bets
In other news, CEO Claire Mazumdar sold 10,000 shares of the company’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $28.42, for a total value of $284,200.00. Following the transaction, the chief executive officer owned 362,152 shares of the company’s stock, valued at $10,292,359.84. This represents a 2.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 28,000 shares of the stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $28.85, for a total value of $807,800.00. Following the transaction, the chief financial officer owned 129,855 shares of the company’s stock, valued at approximately $3,746,316.75. This represents a 17.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 93,950 shares of company stock worth $2,492,515 over the last ninety days. Company insiders own 13.80% of the company’s stock.
Analysts Set New Price Targets
Read Our Latest Research Report on BCAX
Bicara Therapeutics Price Performance
Shares of NASDAQ BCAX opened at $27.73 on Friday. The company has a 50 day simple moving average of $24.42 and a 200-day simple moving average of $20.81. The company has a market capitalization of $1.82 billion, a P/E ratio of -9.97 and a beta of -0.81. Bicara Therapeutics Inc. has a 1 year low of $9.57 and a 1 year high of $30.99.
Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.21). As a group, research analysts expect that Bicara Therapeutics Inc. will post -3.42 EPS for the current year.
About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.
The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
Featured Articles
- Five stocks we like better than Bicara Therapeutics
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Want to see what other hedge funds are holding BCAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bicara Therapeutics Inc. (NASDAQ:BCAX – Free Report).
Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
